Valthos Raises $30 Million for Next-Gen Biodefense

Valthos, a New York-based biodefense startup, has launched out of stealth with $30 million in seed funding from the OpenAI Startup Fund, Lux Capital, and Founders Fund. The company brings together a team from Palantir, DeepMind, the Broad Institute, and the Arc Institute, aiming to build the “tech stack for biodefense.”

As synthetic biology and advanced AI converge, Valthos is racing to develop systems that can spot dangerous pathogens and update medical countermeasures in real-time, offering a critical new layer of defense as governments and health agencies confront risks never seen before.

"Life itself has become programmable," says Valthos. Valthos sees the emerging landscape as requiring tools that match the speed and complexity of evolving biotechnologies. Their solution promises rapid recognition of infectious agents and the ability to neutralize outbreaks and new threats on a timeline measured in hours, not months.​

Valthos builds AI systems to analyze biological sequences and instantly update medical treatments. Their infrastructure is rooted in distributed software, advanced ML method development, and domain-specific expertise in biotechnology. The goal is to shift medical responses from static, slow-moving stockpiles to a dynamic, precision model capable of adapting to emerging pathogens in real time.​